Catabasis Pharmaceuticals

OverviewSuggest Edit

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of innovative drugs to treat inflammatory conditions. There platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

TypePublic
Founded2008
HQCambridge, US
Websitecatabasis.com

Latest Updates

Employees (est.) (Dec 2018)24(-33%)
Revenue (FY, 2017)$500 K
Share Price (Oct 2019)$5 (-4%)

Key People/Management at Catabasis Pharmaceuticals

Jill C. Milne

Jill C. Milne

Ph.D. Co-Founder and Chief Executive Officer
Deirdre A. Cunnane

Deirdre A. Cunnane

Chief Legal Officer
Joanne M. Donovan

Joanne M. Donovan

Chief Medical Officer and Senior Vice President, Clinical Development
Andrew Nichols

Andrew Nichols

Ph.D. Chief Scientific Officer
Angelika Fretzen

Angelika Fretzen

Ph.D. Senior Vice President, Product Development
Joe Johnston

Joe Johnston

Vice President, Regulatory Affairs
Show more

Catabasis Pharmaceuticals Office Locations

Catabasis Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square B14202
Show all (1)

Catabasis Pharmaceuticals Financials and Metrics

Catabasis Pharmaceuticals Revenue

Catabasis Pharmaceuticals's revenue was reported to be $500 k in FY, 2017
USD

Net income (FY, 2018)

(25.9m)

EBIT (FY, 2018)

(26.4m)

Market capitalization (11-Oct-2019)

57.7m

Closing stock price (11-Oct-2019)

5.0

Cash (31-Dec-2018)

15.3m
Catabasis Pharmaceuticals's current market capitalization is $57.7 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

500.0k

General and administrative expense

8.6m10.1m8.9m9.3m

R&D expense

23.0m25.5m18.7m17.0m

Operating expense total

31.7m35.6m27.6m26.4m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

250.0k

General and administrative expense

2.8m2.6m2.3m2.4m2.4m2.4m2.4m2.4m

R&D expense

6.4m6.8m5.9m5.4m4.5m4.8m5.2m4.2m

Operating expense total

9.2m9.4m8.3m7.8m6.9m7.2m7.6m6.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

62.8m23.6m16.4m15.3m

Inventories

804.0k1.0m

Current Assets

63.6m39.5m17.5m38.9m

PP&E

504.0k568.0k321.0k56.0k
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

81.5m72.7m23.8m24.3m26.5m31.8m29.4m21.7m17.0m49.9m

Current Assets

82.1m73.3m53.4m43.7m48.3m32.8m30.3m22.8m17.9m50.7m

PP&E

230.0k216.0k770.0k718.0k641.0k494.0k442.0k388.0k258.0k51.0k

Total Assets

82.5m73.7m54.3m44.6m48.9m33.4m30.8m23.3m18.3m50.8m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(32.6m)(36.1m)(27.4m)(25.9m)

Depreciation and Amortization

202.0k395.0k304.0k119.0k

Inventories

(450.0k)(229.0k)

Accounts Payable

196.0k77.0k(632.0k)662.0k
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(9.4m)(18.9m)(27.3m)(7.9m)(14.8m)(21.9m)(7.7m)(14.1m)

Depreciation and Amortization

195.0k300.0k88.0k165.0k237.0k62.0k105.0k

Accounts Payable

2.5m1.8m1.6m210.0k178.0k(468.0k)650.0k(203.0k)342.0k(402.0k)

Cash From Operating Activities

(18.0m)(24.9m)(8.1m)(13.8m)(21.2m)(6.8m)(12.4m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Catabasis Pharmaceuticals Online and Social Media Presence

Embed Graph

Catabasis Pharmaceuticals News and Updates

Duchenne Muscular Dystrophy - Pipeline Review, H2 including key players Capricor Therapeutics , Catabasis Pharmaceuticals

A new independent 279 page research with title 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2018' guarantees you will remain better informed than your competition. Posted via Industry Today. Follow us on Twitter @IndustryToday

Catabasis Pharmaceuticals Blogs

Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress

Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress Content Import Thu, 08/08/2019 - 08:05 Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress August 8, 2019 at 8:05 AM EDT …

Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors

Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors Content Import Wed, 08/07/2019 - 08:00 Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors August 7, 2019 at 8:00 AM EDT This release is a backfill from a News Wire…

Hugh M. Cole (W/19)

Hugh M. Cole (W/19) Justin.Howard@… Tue, 08/06/2019 - 13:24 Hugh M. Cole Chief Business Officer and Head of Corporate Development, Jounce Therapeutics Hugh M. Cole has served as a member of our Board of Directors since July 2019. Mr. Cole is currently the Chief Bu…

Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference Content Import Tue, 08/06/2019 - 08:00 Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference August 6, 2019 at 8:00 AM EDT This release is a backfil…

Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th

The Company will host a conference call at 8:30am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 25, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2019 financial results before the Nasdaq Global Market open on Thursday,

Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference

Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference Content Import Thu, 06/27/2019 - 08:00 Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent a…
Show more

Catabasis Pharmaceuticals Frequently Asked Questions

  • When was Catabasis Pharmaceuticals founded?

    Catabasis Pharmaceuticals was founded in 2008.

  • Who are Catabasis Pharmaceuticals key executives?

    Catabasis Pharmaceuticals's key executives are Jill C. Milne, Deirdre A. Cunnane and Joanne M. Donovan.

  • How many employees does Catabasis Pharmaceuticals have?

    Catabasis Pharmaceuticals has 24 employees.

  • Who are Catabasis Pharmaceuticals competitors?

    Competitors of Catabasis Pharmaceuticals include Frontier Medicines, Amphastar Pharmaceuticals and XtalPi.

  • Where is Catabasis Pharmaceuticals headquarters?

    Catabasis Pharmaceuticals headquarters is located at 1 Kendall Square B14202, Cambridge.

  • Where are Catabasis Pharmaceuticals offices?

    Catabasis Pharmaceuticals has an office in Cambridge.

  • How many offices does Catabasis Pharmaceuticals have?

    Catabasis Pharmaceuticals has 1 office.